Relationship between fortilin levels and coronary ischemia in heart failure

Year 2024, Volume: 10 Issue: 4, 338 - 344, 04.07.2024

Sümeyra Gökçek , Cihan Aydın , Aykut Demirkıran , Şeref Alpsoy

https://doi.org/10.18621/eurj.1447544

Abstract

Objective: Fortilin is a multifunctional protein that protects cells against apoptosis. We aimed to investigate the levels of fortilin in patients with heart failure.

Methods: Patients with ejection fraction (EF) below 40% were divided into two groups according to coronary angiography results: those with ischemic heart failure (Group 1) and those with non-ischemic heart failure (Group 2). Patients with normal anatomy and EF over 50% were included in the control group (Group 3).

Results: A total of 119 patients were prospectively included in the study. A total of 81 patients (41 patients with ischemic heart failure and 40 patients with non-ischemic heart failure) were included in the heart failure group. 38 patients with EF >50 and normal coronary anatomy were included in the control group. There was no significant difference in serum fortilin levels between the study groups (Group 1: 5.5±2.6 ng/mL, Group 2: 6.1±3.8 ng/mL, and Group 3: 5.6±3.6 ng/mL; P=0.693). Fortilin did not show a correlation with any other variables.

Conclusion: In our study, there was no significant difference in fortilin levels between the groups, and no relationship was found between coronary ischemia and fortilin levels in heart failure.

Keywords

Heart failure, fortilin, ejection fraction, pro-BNP

References

• 1. Vitale C, Spoletini I, Rosano GM. Frailty in Heart Failure: Implications for Management. Card Fail Rev. 2018;4(2):104-106. doi:10.15420/cfr.2018.22.2.
• 2. Yang X, Lupón J, Vidán MT, et al. Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2018;7(23):e008251. doi: 10.1161/JAHA.117.008251.
• 3. Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019;21(11):1306-1325. doi:10.1002/ejhf.1594.
• 4. Chunhacha P, Pinkaew D, Sinthujaroen P, Bowles DE, Fujise K. Fortilin inhibits p53, halts cardiomyocyte apoptosis, and protects the heart against heart failure. Cell Death Discov. 2021;7(1):310. doi:10.1038/s41420-021-00692-w.
• 5. Aoyama M, Kishimoto Y, Saita E, et al. High Plasma Levels of Fortilin in Patients with Coronary Artery Disease. Int J Mol Sci. 2022;23(16):8923. doi: 10.3390/ijms23168923
• 6. Pinkaew D, Fujise K. Fortilin: A Potential Target for the Prevention and Treatment of Human Diseases. Adv Clin Chem. 2017;82:265-300. doi:10.1016/bs.acc.2017.06.006.
• 7. Mak TW, Hauck L, Grothe D, Billia F. p53 regulates the cardiac transcriptome. Proc Natl Acad Sci U S A. 2017;114(9):2331-2336. doi:10.1073/pnas.1621436114.
• 8. Chen Y, Fujita T, Zhang D, et al. Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein. J Biol Chem. 2011;286(37):32575-85. doi: 10.1074/jbc.M110.217836.
• 9. Pinkaew D, Chattopadhyay A, King MD, et al. Fortilin binds IRE1α and prevents ER stress from signaling apoptotic cell death. Nat Commun. 2017;8(1):18. doi: 10.1038/s41467-017-00029-1.
• 10. Pinkaew D, Martinez-Hackert E, Jia W, et al. Fortilin interacts with TGF-β1 and prevents TGF-β receptor activation. Commun Biol. 2022;5(1):157. doi: 10.1038/s42003-022-03112-6.
• 11. Pinkaew D, Le RJ, Chen Y, Eltorky M, Teng BB, Fujise K. Fortilin reduces apoptosis in macrophages and promotes atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2013;305:H1519-H1529. doi: 10.1152/ajpheart.00570.2013.
• 12. Nusair SD, Joukhan AN, Rashaid AB, Rababa'h AM. Methomyl induced effect on fortilin and S100A1 in serum and cardiac tissue: Potential biomarkers of toxicity. Hum Exp Toxicol. 2019;38(3):371-377. doi: 10.1177/0960327118814153.
• 13. Bommer UA, Vine KL, Puri P, et al. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin. Cell Commun Signal. 2017;15(1):9. doi: 10.1186/s12964-017-0164-3.
• 14. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14(1):30-38. doi:10.1038/nrcardio.2016.163.